

France CAR-T Cell Therapy Market By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F

<https://marketpublishers.com/r/FA823CD9CC17EN.html>

Date: November 2023

Pages: 90

Price: US\$ 3,500.00 (Single User License)

ID: FA823CD9CC17EN

Abstracts

France CAR-T Cell Therapy Market is anticipated to project impressive growth in the forecast period. The France CAR-T Cell Therapy market in 2023 demonstrates a dynamic landscape, driven by advancements in cellular immunotherapy and a growing focus on personalized medicine. CAR-T (Chimeric Antigen Receptor T-cell) therapy has gained prominence as a revolutionary treatment for certain hematological malignancies.

Key Market Drivers

Increasing Incidence of Hematological Malignancies

France, like many countries, is grappling with a concerning rise in the incidence of hematological malignancies, including leukemia and lymphoma. However, amidst the challenges posed by these diseases, there lies an opportunity for growth and innovation in the healthcare sector, particularly in the realm of CAR-T cell therapy.

Hematological malignancies, characterized by the abnormal growth of blood-forming tissues, have been on the rise in France. Leukemia and lymphoma, in particular, have witnessed an uptick in new cases. This surge in incidence has created an urgent need for novel and effective treatment modalities, opening a window of opportunity for advanced therapies like CAR-T cell therapy.

CAR-T cell therapy represents a paradigm shift in cancer treatment. Unlike traditional approaches, CAR-T therapy harnesses the power of a patient's own immune system, genetically modifying T cells to specifically target cancer cells. This targeted precision is especially relevant in hematological malignancies, where specific antigens on cancer cells can be identified and attacked by engineered T cells.

As the incidence of hematological malignancies rises, there is an increasing need for diverse and effective treatment options. CAR-T cell therapy, with its potential to induce durable remissions in certain cases, adds a valuable tool to the oncologist's arsenal. The therapy's ability to address unmet medical needs in relapsed or refractory cases positions it as a promising solution for patients who have exhausted conventional treatments.

The increasing prevalence of hematological malignancies is driving a transformation in the therapeutic landscape. CAR-T cell therapy, once considered experimental, is gaining acceptance as a standard of care in certain cases. This shift is not only reshaping treatment algorithms but is also fostering a climate where patients and healthcare providers are more open to exploring innovative and personalized approaches to cancer care.

While the surge in hematological malignancies poses a significant public health challenge, it also carries economic implications. The economic burden associated with treating these diseases underscores the importance of investing in advanced therapies that offer not only clinical benefits but also potential cost-effectiveness in the long run. CAR-T cell therapy, by providing durable responses, may reduce the need for extensive and costly long-term treatments.

Advancements in Cellular Immunotherapy

In the ever-evolving landscape of cancer treatment, advancements in cellular immunotherapy have emerged as a beacon of hope, particularly in the context of Chimeric Antigen Receptor T-cell (CAR-T) therapy. France is witnessing a notable surge in the development and adoption of CAR-T cell therapies, largely propelled by continuous advancements in cellular immunotherapy.

Cellular immunotherapy represents a revolutionary approach to cancer treatment, leveraging the power of the patient's immune system to target and eliminate cancer cells. Within this paradigm, CAR-T cell therapy stands out as a pioneering strategy, involving the genetic modification of a patient's T cells to express chimeric antigen receptors, enhancing their ability to recognize and attack cancer cells.

Advancements in cellular immunotherapy have led to the refinement of CAR-T cell therapy, enhancing its targeting precision and specificity. Improved understanding of cancer cell antigens and sophisticated genetic engineering techniques enable the development of CAR-T cells with heightened selectivity, reducing the risk of off-target effects and increasing the therapy's overall safety profile.

As cancer cells can develop resistance to traditional treatments, the ability of CAR-T cell therapy to overcome resistance mechanisms has become a key driver in its adoption. Advances in cellular immunotherapy contribute to the design of CAR-T cells that can effectively recognize and eliminate cancer cells, even those that have become resistant to other treatment modalities.

Cellular immunotherapy's progress extends beyond CAR-T cell therapy, influencing the development of other innovative approaches. This broader exploration of cellular-based treatments contributes to a growing understanding of their potential applications in various cancer types, fostering a diverse and robust ecosystem of immunotherapeutic options.

Advancements in cellular immunotherapy include innovations in manufacturing processes for CAR-T cell therapies. Streamlining production methods, optimizing scalability, and reducing costs are critical aspects that contribute to the growth of the CAR-T cell therapy market. Efforts to make these therapies more accessible and commercially viable are fueled by ongoing advancements in cellular manufacturing techniques.

Regulatory Support and Approvals

In the dynamic field of medical innovation, regulatory support and approvals play a pivotal role in shaping the trajectory of emerging therapies. This is particularly evident in the context of Chimeric Antigen Receptor T-cell (CAR-T) therapy in France, where a supportive regulatory environment acts as a catalyst for the growth of this revolutionary treatment option.

Regulatory agencies serve as guardians of public health, meticulously evaluating new therapies to ensure they meet stringent safety and efficacy standards. In the case of CAR-T cell therapy, which involves genetic modification of a patient's own immune cells, regulatory scrutiny is paramount. The endorsement of regulatory bodies provides assurance to healthcare professionals and patients regarding the safety and effectiveness of CAR-T treatments.

France's commitment to efficient and timely approval processes contributes significantly to the growth of the CAR-T cell therapy market. Streamlined regulatory pathways enable swift market entry for new therapies, reducing delays and allowing patients to access innovative treatments without prolonged waiting periods. This expeditious approval process facilitates the translation of groundbreaking research into real-world clinical applications.

A supportive regulatory environment fosters a climate conducive to innovation and research investments. Pharmaceutical companies and research institutions are more inclined to allocate resources to the development of CAR-T cell therapies when they perceive a clear and navigable regulatory pathway. This, in turn, fuels advancements in technology, manufacturing, and therapeutic applications.

Successful growth in the CAR-T cell therapy market is often the result of collaborative efforts between regulatory bodies and industry stakeholders. Ongoing communication and collaboration facilitate a mutual understanding of the evolving landscape, enabling regulatory agencies to adapt to scientific advancements while ensuring that new therapies adhere to established safety and quality standards.

CAR-T cell therapy, with its personalized and complex nature, presents unique logistical and ethical challenges. Regulatory support is instrumental in addressing these challenges by establishing clear guidelines for patient eligibility, manufacturing standards, and post-treatment monitoring. Such guidelines provide a framework for healthcare professionals and contribute to the overall success and acceptance of CAR-T cell therapy.

Increased Awareness and Acceptance

In the landscape of cutting-edge medical treatments, the journey from scientific breakthrough to widespread acceptance often hinges on increased awareness among healthcare professionals and the public. This is particularly true for Chimeric Antigen Receptor T-cell (CAR-T) therapy in France, where heightened awareness and acceptance are key drivers propelling the growth of this innovative approach to cancer treatment.

Enhanced awareness among healthcare professionals is a linchpin for the success of CAR-T cell therapy. Continuous education and training programs ensure that physicians, nurses, and other healthcare providers are well-informed about the therapeutic benefits, potential side effects, and patient selection criteria associated with CAR-T treatments. This knowledge equips healthcare professionals to make informed decisions and recommend CAR-T therapy when appropriate.

A crucial aspect of increasing awareness lies in empowering patients with knowledge about CAR-T cell therapy. Patient education initiatives help individuals understand the science behind CAR-T, the treatment process, and the potential outcomes. Informed patients are more likely to actively engage in discussions with their healthcare providers, inquire about treatment options, and consider CAR-T therapy as a viable choice in their cancer journey.

The collaboration between patient advocacy groups and healthcare professionals plays a pivotal role in raising awareness. These groups serve as conduits of information, offering support, resources, and a platform for patients and their families to share experiences. By amplifying the voices of those who have undergone CAR-T therapy, advocacy groups contribute to a growing narrative of success and hope, fostering increased acceptance.

Sharing success stories is a powerful tool in building awareness and acceptance. As more patients experience positive outcomes with CAR-T cell therapy, these stories serve as beacons of hope for others facing hematological malignancies. Media campaigns, testimonials, and patient testimonials contribute to a positive narrative surrounding CAR-T, dispelling myths and reducing apprehensions.

Participation in and promotion of professional conferences and symposia dedicated to cancer and immunotherapy are essential components of increasing awareness. These

platforms provide opportunities for experts, researchers, and clinicians to share the latest advancements in CAR-T therapy, fostering a collaborative environment that drives awareness and acceptance within the medical community.

Key Market Challenges

High Treatment Costs

One of the primary challenges faced by the France CAR-T cell therapy market is the high cost associated with these innovative treatments. The complex and personalized nature of CAR-T therapy, along with the intricate manufacturing processes involved, contribute to elevated production costs. This financial burden poses challenges for both patients seeking access to the therapy and healthcare systems aiming to integrate it into standard care.

Logistical Complexities

CAR-T cell therapy involves a highly intricate and personalized process, from collecting a patient's T cells to genetically modifying them and reintroducing them into the patient. The logistics of this procedure, including transportation of patient samples and the final CAR-T product, pose challenges. Maintaining the integrity of these cells throughout the process requires precise coordination and infrastructure.

Limited Therapeutic Indications

As of now, CAR-T cell therapy has primarily demonstrated success in the treatment of certain hematological malignancies, such as leukemia and lymphoma. Expanding its therapeutic indications to solid tumors presents a significant challenge. Research is ongoing, but the complexity of the tumor microenvironment and antigen selection poses obstacles in developing effective CAR-T treatments for solid cancers.

Key Market Trends

Expansion of Indications Beyond Hematological Malignancies

One of the most notable trends on the horizon is the expansion of CAR-T cell therapy indications beyond hematological malignancies. While CAR-T has shown remarkable success in treating leukemia and lymphoma, ongoing research aims to extend its application to solid tumors. This shift could potentially widen the therapeutic scope of

CAR-T therapy, offering new hope to patients with various cancer types.

Next-generation CAR-T Constructs

The evolution of CAR-T constructs is a key trend set to redefine the therapy's efficacy and safety profiles. Next-generation CAR-T designs are being developed with enhanced features, such as dual-targeting capabilities, improved persistence, and reduced toxicity. These advancements aim to further optimize the therapeutic potential of CAR-T cells while minimizing adverse effects.

Allogeneic CAR-T Therapies

Allogeneic CAR-T therapies, derived from donor cells rather than the patient's own cells, are emerging as a trend with the potential to address manufacturing challenges and improve accessibility. Overcoming the limitations associated with autologous CAR-T therapy, allogeneic approaches could streamline production processes and make CAR-T treatments more readily available to a broader patient population.

Segmental Insights

Tumor Type Insights

Based on Tumor Type, Hematological malignancies are poised to assert dominance in the French CAR-T cell therapy market due to several compelling factors. Firstly, the prevalence of hematologic cancers, such as lymphomas and leukemias, remains high in France, necessitating advanced and targeted treatment options. CAR-T cell therapy has demonstrated remarkable efficacy in treating these malignancies by harnessing the patient's immune system to specifically target cancer cells. Additionally, the robust research infrastructure and clinical expertise in France contribute to the advancement of CAR-T cell therapy, making it a forefront option for hematological malignancies. The therapeutic landscape is evolving rapidly, with ongoing clinical trials and collaborations between academic institutions and biopharmaceutical companies further propelling the growth of CAR-T cell therapies for hematological cancers. As a result, the confluence of clinical need, scientific innovation, and collaborative efforts positions hematological malignancies at the forefront of the CAR-T cell therapy market in France.

End User

Based on End User, Hospitals are poised to dominate as the primary end user in the

France CAR-T cell therapy market due to their central role in the delivery of specialized medical treatments. CAR-T cell therapy, being a highly advanced and complex form of immunotherapy, requires specialized infrastructure and skilled healthcare professionals for administration and patient monitoring. Hospitals in France, with their state-of-the-art facilities and multidisciplinary teams, are well-equipped to handle the intricacies of CAR-T cell therapy. Moreover, hospitals serve as focal points for collaboration between healthcare providers, researchers, and pharmaceutical companies, facilitating seamless integration of cutting-edge therapies into clinical practice. The centralized nature of healthcare delivery in hospitals also ensures efficient coordination among various departments involved in the CAR-T cell therapy process, including diagnostics, oncology, and intensive care. As a result, hospitals emerge as the key end users driving the widespread adoption and success of CAR-T cell therapy in the French healthcare landscape.

Regional Insights

Northern France is poised to dominate the CAR-T cell therapy market in the country due to a convergence of strategic factors. The region hosts several renowned research and academic institutions specializing in oncology and immunotherapy, fostering a rich ecosystem for scientific advancements and clinical innovation. Moreover, the presence of leading pharmaceutical companies and biotech firms with a focus on developing cutting-edge therapies contributes to the region's prominence. The robust infrastructure of medical facilities and hospitals in Northern France, coupled with a well-established network of healthcare professionals, positions the region as a hub for the administration and management of CAR-T cell therapy. Additionally, Northern France's geographical proximity to key European markets facilitates efficient distribution and collaboration, further enhancing its competitive advantage in the CAR-T cell therapy landscape. As a result, the combination of research excellence, industry presence, and logistical advantages solidifies Northern France's position as a dominant player in the rapidly evolving CAR-T cell therapy market.

Key Market Players

Gilead Sciences, Inc

Novartis International AG

Bristol Myers Squibb Co

Abbvie France, S.L.U.

Cellectis SA

AMGEN S.A.

Pfizer

Merck & Co. Inc

Johnson & Johnson Sant? Beaut? France

Sangamo Therapeutics France

Report Scope:

In this report, the France CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

France CAR-T Cell Therapy Market, By Product Type:

Yescarta (Axicabtagene Ciloleucel)

Kymriah (Tisagenlecleucel)

Others

France CAR-T Cell Therapy Market, By Tumor Type:

Hematological Malignancies

Solid Tumors

France CAR-T Cell Therapy Market, By Indication:

Diffused Large B-Cell Lymphoma (DLBCL)

Acute Lymphoblastic Leukemia (ALL)

Follicular Lymphoma (FL)

Mantle Cell Lymphoma (MCL)

Others

France CAR-T Cell Therapy Market, By Treatment Type:

Single Treatment

Combination Treatment

France CAR-T Cell Therapy Market, By Targeted Antigen:

CD 19

BCMA (B-Cell Maturation Antigen)

Others

France CAR-T Cell Therapy Market, By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

France CAR-T Cell Therapy Market, By Region:

Northern France

Southern France

Western France

Central France

Eastern France

Southwestern France

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the France CAR-T Cell Therapy Market.

Available Customizations:

France CAR-T Cell Therapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. FRANCE CAR-T CELL THERAPY MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
 - 5.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)

- 5.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
- 5.2.4. By Treatment Type (Single Treatment, Combination Treatment)
- 5.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
- 5.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 5.2.7. By Region
- 5.2.8. By Company (2022)
- 5.3. Market Map
 - 5.3.1. By Product Type
 - 5.3.2. By Tumor Type
 - 5.3.3. By Indication
 - 5.3.4. By Treatment Type
 - 5.3.5. By Targeted Antigen
 - 5.3.6. By End User
 - 5.3.7. By Region

6. NORTHERN FRANCE CAR-T CELL THERAPY MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
 - 6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
 - 6.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
 - 6.2.4. By Treatment Type (Single Treatment, Combination Treatment)
 - 6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
 - 6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

7. SOUTHERN FRANCE CAR-T CELL THERAPY MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)
 - 7.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
 - 7.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic

Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

7.2.4. By Treatment Type (Single Treatment, Combination Treatment)

7.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

7.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

8. WESTERN FRANCE CAR-T CELL THERAPY MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)

8.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)

8.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

8.2.4. By Treatment Type (Single Treatment, Combination Treatment)

8.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

8.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

9. CENTRAL FRANCE CAR-T CELL THERAPY MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)

9.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)

9.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

9.2.4. By Treatment Type (Single Treatment, Combination Treatment)

9.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

9.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

10. EASTERN FRANCE CAR-T CELL THERAPY MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah

(Tisagenlecleucel), Others)

10.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)

10.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

10.2.4. By Treatment Type (Single Treatment, Combination Treatment)

10.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

10.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

11. SOUTHWESTERN FRANCE CAR-T CELL THERAPY MARKET OUTLOOK

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others)

11.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)

11.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

11.2.4. By Treatment Type (Single Treatment, Combination Treatment)

11.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

11.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

12. MARKET DYNAMICS

12.1. Drivers

12.2. Challenges

13. MARKET TRENDS & DEVELOPMENTS

13.1. Recent Developments

13.2. Mergers & Acquisitions

13.3. Product Launches

14. POLICY & REGULATORY LANDSCAPE

15. PORTER'S FIVE FORCES ANALYSIS

- 15.1. Competition in the Industry
- 15.2. Potential of New Entrants
- 15.3. Power of Suppliers
- 15.4. Power of Customers
- 15.5. Threat of Substitute Products

16. FRANCE ECONOMIC PROFILE

17. COMPETITIVE LANDSCAPE

- 17.1. Business Overview
- 17.2. Product Offerings
- 17.3. Recent Developments
- 17.4. Financials (As Reported)
- 17.5. Key Personnel
- 17.6. SWOT Analysis
 - 17.6.1. Gilead Sciences, Inc
 - 17.6.2. Novartis International AG
 - 17.6.3. Bristol Myers Squibb Co
 - 17.6.4. Abbvie France, S.L.U.
 - 17.6.5. Cellectis SA
 - 17.6.6. AMGEN S.A.
 - 17.6.7. Pfizer
 - 17.6.8. Merck & Co. Inc
 - 17.6.9. Johnson & Johnson Sant? Beaut? France
 - 17.6.10. Sangamo Therapeutics France

18. STRATEGIC RECOMMENDATIONS

I would like to order

Product name: France CAR-T Cell Therapy Market By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F

Product link: <https://marketpublishers.com/r/FA823CD9CC17EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FA823CD9CC17EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970